Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 245 entries
Sorted by: Best Match Show Resources per page
Monomeric Octahedral Ruthenium(II) Complex Enabled meta-C-H Nitration of Arenes with Removable Auxiliaries.

Organic letters

Fan Z, Li J, Lu H, Wang DY, Wang C, Uchiyama M, Zhang A.
PMID: 28574271
Org Lett. 2017 Jun 16;19(12):3199-3202. doi: 10.1021/acs.orglett.7b01297. Epub 2017 Jun 02.

A removable oxime-assisted meta-C-H nitration of arenes is reported. Mechanistic investigations and DFT calculations reveal a new monomeric octahedral ruthenium(II) complex is responsible for the meta-selective nitration. Dioxygen as a cooxidant is crucial for achieving high conversion and good...

Cite
Fan Z, Li J, Lu H, et al. Monomeric Octahedral Ruthenium(II) Complex Enabled meta-C-H Nitration of Arenes with Removable Auxiliaries. Org Lett. 2017;19(12):3199-3202doi: 10.1021/acs.orglett.7b01297.
Fan, Z., Li, J., Lu, H., Wang, D. Y., Wang, C., Uchiyama, M., & Zhang, A. (2017). Monomeric Octahedral Ruthenium(II) Complex Enabled meta-C-H Nitration of Arenes with Removable Auxiliaries. Organic letters, 19(12), 3199-3202. https://doi.org/10.1021/acs.orglett.7b01297
Fan, Zhoulong, et al. "Monomeric Octahedral Ruthenium(II) Complex Enabled meta-C-H Nitration of Arenes with Removable Auxiliaries." Organic letters vol. 19,12 (2017): 3199-3202. doi: https://doi.org/10.1021/acs.orglett.7b01297
Fan Z, Li J, Lu H, Wang DY, Wang C, Uchiyama M, Zhang A. Monomeric Octahedral Ruthenium(II) Complex Enabled meta-C-H Nitration of Arenes with Removable Auxiliaries. Org Lett. 2017 Jun 16;19(12):3199-3202. doi: 10.1021/acs.orglett.7b01297. Epub 2017 Jun 02. PMID: 28574271.
Copy Download .nbib Format: NLM
Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder.

International journal of psychiatry in clinical practice

Xie F, Despiegel N, Danchenko N, Hansen K.
PMID: 24946123
Int J Psychiatry Clin Pract. 2009;13(1):59-69. doi: 10.1080/13651500802450506.

Objective. To compare the costs and effectiveness of escitalopram with venlafaxine and fluvoxamine for treatment of major depressive disorder (MDD) from the societal perspective in Singapore. Methods. The decision analytical model consisted of two pathways, one for primary care...

Cite
Xie F, Despiegel N, Danchenko N, et al. Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. Int J Psychiatry Clin Pract. 2009;13(1):59-69doi: 10.1080/13651500802450506.
Xie, F., Despiegel, N., Danchenko, N., & Hansen, K. (2009). Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. International journal of psychiatry in clinical practice, 13(1), 59-69. https://doi.org/10.1080/13651500802450506
Xie, Feng, et al. "Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder." International journal of psychiatry in clinical practice vol. 13,1 (2009): 59-69. doi: https://doi.org/10.1080/13651500802450506
Xie F, Despiegel N, Danchenko N, Hansen K. Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. Int J Psychiatry Clin Pract. 2009;13(1):59-69. doi: 10.1080/13651500802450506. PMID: 24946123.
Copy Download .nbib Format: NLM
Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine.

International journal of psychiatry in clinical practice

Pallanti S, Sandner C.
PMID: 24941363
Int J Psychiatry Clin Pract. 2007;11(3):233-8. doi: 10.1080/13651500701419685.

The advent of the selective serotonin reuptake inhibitors (SSRIs) is generally considered to have improved the treatment of depression. Head-to-head trials comparing SSRIs to each other have shown little difference in efficacy among agents. The main differences between the...

Cite
Pallanti S, Sandner C. Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine. Int J Psychiatry Clin Pract. 2007;11(3):233-8doi: 10.1080/13651500701419685.
Pallanti, S., & Sandner, C. (2007). Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine. International journal of psychiatry in clinical practice, 11(3), 233-8. https://doi.org/10.1080/13651500701419685
Pallanti, Stefano, and Sandner, Cláudio. "Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine." International journal of psychiatry in clinical practice vol. 11,3 (2007): 233-8. doi: https://doi.org/10.1080/13651500701419685
Pallanti S, Sandner C. Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine. Int J Psychiatry Clin Pract. 2007;11(3):233-8. doi: 10.1080/13651500701419685. PMID: 24941363.
Copy Download .nbib Format: NLM
Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease.

American journal of neurodegenerative disease

Lauterbach EC.
PMID: 27073741
Am J Neurodegener Dis. 2016 Mar 01;5(1):29-51. eCollection 2016.

Anxiety is common in the Mild Cognitive Impairment (MCI) stage of Alzheimer's disease (AD) and the pre-motor stages of Parkinson's disease (PD). A concomitant and possible cause of this anxiety is microglial activation, also considered a key promoter of...

Cite
Lauterbach EC. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. Am J Neurodegener Dis. 2016;5(1):29-51
Lauterbach, E. C. (2016). Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. American journal of neurodegenerative disease, 5(1), 29-51.
Lauterbach, Edward C. "Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease." American journal of neurodegenerative disease vol. 5,1 (2016): 29-51.
Lauterbach EC. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. Am J Neurodegener Dis. 2016 Mar 01;5(1):29-51. eCollection 2016. PMID: 27073741; PMCID: PMC4788730.
Copy Download .nbib Format: NLM
Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities.

CNS drugs

Soyka M.
PMID: 27520754
CNS Drugs. 1997 Apr;7(4):313-27. doi: 10.2165/00023210-199707040-00004.

Most psychotropic drugs, such as antipsychotics, lithium and tricyclic antidepressants, do not improve alcohol (ethanol) abstinence rates, at least in alcohol-dependent patients who do not have a comorbid psychiatric disorder. In recent years, numerous studies have been published that...

Cite
Soyka M. Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities. CNS Drugs. 1997;7(4):313-27doi: 10.2165/00023210-199707040-00004.
Soyka, M. (1997). Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities. CNS drugs, 7(4), 313-27. https://doi.org/10.2165/00023210-199707040-00004
Soyka, M. "Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities." CNS drugs vol. 7,4 (1997): 313-27. doi: https://doi.org/10.2165/00023210-199707040-00004
Soyka M. Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities. CNS Drugs. 1997 Apr;7(4):313-27. doi: 10.2165/00023210-199707040-00004. PMID: 27520754.
Copy Download .nbib Format: NLM
Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients.

Annals of general psychiatry

Yoshimura R, Kishi T, Hori H, Atake K, Katsuki A, Nakano-Umene W, Ikenouchi-Sugita A, Iwata N, Nakamura J.
PMID: 25089150
Ann Gen Psychiatry. 2014 Jul 09;13:19. doi: 10.1186/1744-859X-13-19. eCollection 2014.

BACKGROUND: We investigated the association between serum proBDNF, a precursor of brain-derived neurotrophic factor (BDNF), and response to fluvoxamine in patients with major depressive disorder (MDD) using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision...

Cite
Yoshimura R, Kishi T, Hori H, et al. Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients. Ann Gen Psychiatry. 2014;13:19doi: 10.1186/1744-859X-13-19.
Yoshimura, R., Kishi, T., Hori, H., Atake, K., Katsuki, A., Nakano-Umene, W., Ikenouchi-Sugita, A., Iwata, N., & Nakamura, J. (2014). Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients. Annals of general psychiatry, 1319. https://doi.org/10.1186/1744-859X-13-19
Yoshimura, Reiji, et al. "Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients." Annals of general psychiatry vol. 13 (2014): 19. doi: https://doi.org/10.1186/1744-859X-13-19
Yoshimura R, Kishi T, Hori H, Atake K, Katsuki A, Nakano-Umene W, Ikenouchi-Sugita A, Iwata N, Nakamura J. Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients. Ann Gen Psychiatry. 2014 Jul 09;13:19. doi: 10.1186/1744-859X-13-19. eCollection 2014. PMID: 25089150; PMCID: PMC4118273.
Copy Download .nbib Format: NLM
Fluvoxamine is ineffective in the treatment of enuresis in children and adolescents: an open-label pilot study.

Human psychopharmacology

Toren P, Eldar S, Laor N, Wolmer L, Samuel E, Weizman R.
PMID: 12404568
Hum Psychopharmacol. 2001 Jun;16(4):327-332. doi: 10.1002/hup.301.

Tricyclic antidepressants possess established antienuretic properties. The selective serotonin reuptake inhibitors (SSRIs) have similar antidepressant properties to the tricyclic antidepressants and a safer side effect profile. The aim of the present study was to evaluate the antienuretic efficacy of...

Cite
Toren P, Eldar S, Laor N, et al. Fluvoxamine is ineffective in the treatment of enuresis in children and adolescents: an open-label pilot study. Hum Psychopharmacol. 2001;16(4):327-332doi: 10.1002/hup.301.
Toren, P., Eldar, S., Laor, N., Wolmer, L., Samuel, E., & Weizman, R. (2001). Fluvoxamine is ineffective in the treatment of enuresis in children and adolescents: an open-label pilot study. Human psychopharmacology, 16(4), 327-332. https://doi.org/10.1002/hup.301
Toren, Paz, et al. "Fluvoxamine is ineffective in the treatment of enuresis in children and adolescents: an open-label pilot study." Human psychopharmacology vol. 16,4 (2001): 327-332. doi: https://doi.org/10.1002/hup.301
Toren P, Eldar S, Laor N, Wolmer L, Samuel E, Weizman R. Fluvoxamine is ineffective in the treatment of enuresis in children and adolescents: an open-label pilot study. Hum Psychopharmacol. 2001 Jun;16(4):327-332. doi: 10.1002/hup.301. PMID: 12404568.
Copy Download .nbib Format: NLM
Electrocardiographic alterations as a result of acute intoxication with fluvoxamine and pipamperone.

Clinical drug investigation

Gallerani M, Grassi L, Ferrari F, Calò G, Manfredini R.
PMID: 18370468
Clin Drug Investig. 1998;15(1):64-8. doi: 10.2165/00044011-199815010-00009.

No abstract available.

Cite
Gallerani M, Grassi L, Ferrari F, et al. Electrocardiographic alterations as a result of acute intoxication with fluvoxamine and pipamperone. Clin Drug Investig. 1998;15(1):64-8doi: 10.2165/00044011-199815010-00009.
Gallerani, M., Grassi, L., Ferrari, F., Calò, G., & Manfredini, R. (1998). Electrocardiographic alterations as a result of acute intoxication with fluvoxamine and pipamperone. Clinical drug investigation, 15(1), 64-8. https://doi.org/10.2165/00044011-199815010-00009
Gallerani, M, et al. "Electrocardiographic alterations as a result of acute intoxication with fluvoxamine and pipamperone." Clinical drug investigation vol. 15,1 (1998): 64-8. doi: https://doi.org/10.2165/00044011-199815010-00009
Gallerani M, Grassi L, Ferrari F, Calò G, Manfredini R. Electrocardiographic alterations as a result of acute intoxication with fluvoxamine and pipamperone. Clin Drug Investig. 1998;15(1):64-8. doi: 10.2165/00044011-199815010-00009. PMID: 18370468.
Copy Download .nbib Format: NLM
Biological therapies for obsessive-compulsive disorder.

Journal of psychiatric practice

Fallon BA, Mathew SJ.
PMID: 15990479
J Psychiatr Pract. 2000 May;6(3):113-28. doi: 10.1097/00131746-200005000-00002.

Two treatments have demonstrated efficacy in OCD, exposure and response (ritual) prevention (EX/RP) and pharmacotherapy with serotonin reuptake inhibitors (SRIs). In this article, which is the third in a three-part series, the authors present an overview of the role...

Cite
Fallon BA, Mathew SJ. Biological therapies for obsessive-compulsive disorder. J Psychiatr Pract. 2000;6(3):113-28doi: 10.1097/00131746-200005000-00002.
Fallon, B. A., & Mathew, S. J. (2000). Biological therapies for obsessive-compulsive disorder. Journal of psychiatric practice, 6(3), 113-28. https://doi.org/10.1097/00131746-200005000-00002
Fallon, B A, and Mathew, S J. "Biological therapies for obsessive-compulsive disorder." Journal of psychiatric practice vol. 6,3 (2000): 113-28. doi: https://doi.org/10.1097/00131746-200005000-00002
Fallon BA, Mathew SJ. Biological therapies for obsessive-compulsive disorder. J Psychiatr Pract. 2000 May;6(3):113-28. doi: 10.1097/00131746-200005000-00002. PMID: 15990479.
Copy Download .nbib Format: NLM
SSRI efficacy-finding the right dose.

Journal of psychiatric practice

Caley CF, Kando JC.
PMID: 15985852
J Psychiatr Pract. 2002 Jan;8(1):33-40. doi: 10.1097/00131746-200201000-00005.

The selective serotonin reuptake inhibitors (SSRIs) are a class of effective, well-tolerated antidepressants. They have a number of benefits compared with the tricyclic antidepressants (TCAs) including improved safety in overdose, reduced side-effect burden, and uncomplicated dosing regimens. To avoid...

Cite
Caley CF, Kando JC. SSRI efficacy-finding the right dose. J Psychiatr Pract. 2002;8(1):33-40doi: 10.1097/00131746-200201000-00005.
Caley, C. F., & Kando, J. C. (2002). SSRI efficacy-finding the right dose. Journal of psychiatric practice, 8(1), 33-40. https://doi.org/10.1097/00131746-200201000-00005
Caley, Charles F, and Kando, Judith C. "SSRI efficacy-finding the right dose." Journal of psychiatric practice vol. 8,1 (2002): 33-40. doi: https://doi.org/10.1097/00131746-200201000-00005
Caley CF, Kando JC. SSRI efficacy-finding the right dose. J Psychiatr Pract. 2002 Jan;8(1):33-40. doi: 10.1097/00131746-200201000-00005. PMID: 15985852.
Copy Download .nbib Format: NLM
Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats.

Journal of anesthesia

Otsuka N, Kiuchi Y, Yokogawa F, Masuda Y, Oguchi K, Hosoyamada A.
PMID: 14566514
J Anesth. 2001;15(3):154-8. doi: 10.1007/s005400170018.

PURPOSE: For assessment of the antinociceptive potency of antidepressants, we compared the antinociceptive effects of serotonin selective reuptake inhibitors (SSRIs) and classical tricyclic antidepressants (TCAs) in rats. We also attempted to elucidate the monoamine receptor subtypes predominantly involved in...

Cite
Otsuka N, Kiuchi Y, Yokogawa F, et al. Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats. J Anesth. 2001;15(3):154-8doi: 10.1007/s005400170018.
Otsuka, N., Kiuchi, Y., Yokogawa, F., Masuda, Y., Oguchi, K., & Hosoyamada, A. (2001). Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats. Journal of anesthesia, 15(3), 154-8. https://doi.org/10.1007/s005400170018
Otsuka, N, et al. "Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats." Journal of anesthesia vol. 15,3 (2001): 154-8. doi: https://doi.org/10.1007/s005400170018
Otsuka N, Kiuchi Y, Yokogawa F, Masuda Y, Oguchi K, Hosoyamada A. Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats. J Anesth. 2001;15(3):154-8. doi: 10.1007/s005400170018. PMID: 14566514.
Copy Download .nbib Format: NLM
QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy.

Annals of general psychiatry

Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, Bonzano A, Piccinelli M, Barale F, De Ferrari GM.
PMID: 15845138
Ann Gen Psychiatry. 2005 Jan 25;4(1):1. doi: 10.1186/1744-859X-4-1.

BACKGROUND: Several antipsychotic agents are known to prolong the QT interval in a dose dependent manner. Corrected QT interval (QTc) exceeding a threshold value of 450 ms may be associated with an increased risk of life threatening arrhythmias. Antipsychotic...

Cite
Sala M, Vicentini A, Brambilla P, et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry. 2005;4(1):1doi: 10.1186/1744-859X-4-1.
Sala, M., Vicentini, A., Brambilla, P., Montomoli, C., Jogia, J. R., Caverzasi, E., Bonzano, A., Piccinelli, M., Barale, F., & De Ferrari, G. M. (2005). QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Annals of general psychiatry, 4(1), 1. https://doi.org/10.1186/1744-859X-4-1
Sala, Michela, et al. "QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy." Annals of general psychiatry vol. 4,1 (2005): 1. doi: https://doi.org/10.1186/1744-859X-4-1
Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, Bonzano A, Piccinelli M, Barale F, De Ferrari GM. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry. 2005 Jan 25;4(1):1. doi: 10.1186/1744-859X-4-1. PMID: 15845138; PMCID: PMC1088007.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 245 entries